Steve Cohen, whose success at SAC Capital made him one of the most successful hedge fund managers on Wall Street, is a worried man.

Ocugen co-founder and CEO Shankar Musunuri, Ph.D. explains what biotech leaders can learn from the Philadelphia Eagles, an ...

The biotech scene may be a risky place to invest. But with so many potential game-changers, the scene is worth watching closely. AI and GLP-1s are two growth engines that could keep top biotech ...

Chinese biotech shares are surging this year on growing optimism over innovative cancer treatments being licensed to western ...

For the biotech sector to improve, its companies need to step up their game. Just 37% of biotech companies reported successful Phase II and Phase III trials in the first quarter, according to ...

As with other biotech stocks, Voyager has trouble with generating consistent profitability. True, in Q4, the company posted EPS of $1.25. This dramatically exceeded the consensus target calling ...

Key Points. The biotech scene may be a risky place to invest. But with so many potential game-changers, the scene is worth watching closely. AI and GLP-1s are two growth engines that could keep ...